Viatris and Mapi Pharma Statement Regarding New Drug Application for GA Depot

March 11, 2024 -- Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for GA Depot 40 mg from the U.S. Food and Drug Administration (FDA). The Companies are...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials